drugset / Trial / NCT00722631

Anti-Inflammatory Effects of Pioglitazone

NCT00722631

Completed 70 enrolled Kurume University
RandomizedSingle-groupOpen-labelTreatment

Summary

There is increasing evidence that inflammation plays a role in progression and destabilization of atherosclerotic plaque. FDG-PET can visualize activated metabolic activity of inflammatory cells. It is possible that FDG-PET can detect atherosclerotic plaque inflammation and that FDG-PET can monitor the effect of pioglitazone on plaque inflammation.

Timeline

Start
2007-05
Primary completion
2009-04
Completion
2012-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule 4 mg Oral
Subject Pioglitazone Small molecule 30 mg Oral